| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $3.54B | +5.8% |
| Gross profit | $1.01B | — |
| Operating income | $0.38B | — |
| Net income | $0.28B | +30.5% |
| Gross margin | 28.7% | Net margin 7.9% |
| Segment | Revenue | Share |
|---|---|---|
| Diagnostics | $2.76B | 78.1% |
| Biopharma Laboratory Services | $0.78B | 22.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $2.52B | 71.3% |
| SG&A | $0.55B | 15.6% |
| Tax & other | $0.10B | 2.9% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
LRCX ・ LVS ・ LDOS ・ LEN ・ LII ・ LLY ・ LIN ・ LYV ・ LMT ・ L ・ LOW ・ LULU
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies